Examples of use for SUNBRIGHT® ME-DT and DT series
-
Examples of use for SUNBRIGHT® ME-DT and DT series
Examples of use for SUNBRIGHT® ME-DT, DT series (PEGPAsp(DET) Block / PAsp(DET) Homo polymer) as polymericmicelles are described in following articles or reviews. The polymeric micelles are effective especially to deliver plasmidDNA and mRNA to tissue by local injection for in vivo, or to toxicity sensitive cells such as primary cells and stem cells.
•Articles
1) M. Ohgidani, K. Furugaki, K. Shinkai, Y. Kunisawa, K. Itaka, K. Kataoka, K. Nakano, Block/homo polyplex micelle-based
GM-CSF gene therapy via intraperitoneal administration elicits antitumor immunity against peritoneal dissemination and
exhibits safety potentials in mice and cynomolgus monkeys. J. Control. Release 167 (3) 238-247 (2013)
2) S. Uchida, K. Itaka, H. Uchida, K. Hayakawa, T. Ogata, T. Ishii, S. Fukushima, K. Osada, K. Kataoka, In vivo messenger RNA
introduction into the central nervous system using polyplex nanomicelle. PLoS One 8 (2) e56220 (2013)
3) T. Endo, K. Itaka, M. Shioyama, S. Uchida, K. Kataoka, Gene transfection to spheroid culture system on micropatterned
culture plate by polyplex nanomicelle: A novel platform of genetically-modified cell transplantation. Drug Deliv. Transl. Res. 2
(5) 398-405 (2012)
4) S. Uchida, K. Itaka, Q. Chen, K. Osada, T. Ishii, M. A. Shibata, M. Harada-Shiba, K. Kataoka,PEGylated polyplex with
optimized PEG shielding enhances gene introduction in lungs by minimizing inflammatory responses. Mol Ther. 20 (6)
1196-1203 (2012)
5) Q. Chen, K. Osada, T. Ishii, M. Oba, S. Uchida, T. A. Tockary, T. Endo, Z. Ge, H. Kinoh, M. R. Kano, K. Itaka, K. Kataoka,
Homo-catiomer integration into PEGylated polyplex micelle from block-catiomer for systemic antiangiogenic gene therapy
for fibrotic pancreatic tumors. Biomaterials 33 (18) 4722-4730 (2012)
6) A. Iriyama, M. Oba, T. Ishii, N. Nishiyama, K. Kataoka, Y. Tamaki, Y. Yanagi, Gene transfer using micellar nanovectors inhibits
choroidal neovascularization in vivo. PLoS One 6 (12) e28560 (2011)
7) A. Iriyama, T. Usui Y. Yanagi, S. Amano M. Oba, K. Miyata, N. Nishiyama, K. Kataoka, Gene transfer using micellar
nanovectors inhibits corneal neovascularization in vivo. Cornea 30 (12) 1423-1427 (2011)
8) M. Han, M. Oba, N. Nishiyama, M. R. Kano, S. Kizaka-Kondoh, K. Kataoka, Enhanced percolation and gene expression in
tumor hypoxia by PEGylated polyplex micelles. Mol. Ther. 17 (8) 1404-1410 (2009)
9) M. Harada-Shiba, I. Takamisawa, K. Miyata, T. Ishii, N. Nishiyama, K. Itaka, K. Kangawa, F. Yoshihara, Y. Asada, K.
Hatakeyama, N. Nagaya, K. Kataoka, Intratracheal gene transfer of adrenomedullin using polyplex nanomicelles attenuates
monocrotaline-induced pulmonary hypertension in rats. Mol. Ther. 17 (7) 1180-1186 (2009)
10) K. Itaka, S. Ohba, K. Miyata, H. Kawaguchi, K. Nakamura, T. Takato, U. -I. Chung, K. Kataoka,Bone regeneration by
regulated in vivo gene transfer using biocompatible polyplex nanomicelles. Mol. Ther. 15 (9) 1655-1662 (2007)
11) D. Akagi, M. Oba, H. Koyama, N. Nishiyama, S. Fukushima, T. Miyata, H. Nagawa, K. Kataoka,Biocompatible micellar
nanovectors achieve efficient gene transfer to vascular lesions without cytotoxicity and thrombus formation. Gene Ther. 14
(13) 1029-1038 (2007)
•Reviews
1) K. Miyata, N. Nishiyama, K. Kataoka, Rational design of smart supramolecular assemblies for gene delivery: Chemical
challenges in the creation of artificial viruses. Chem. Soc. Rev. 41 (7) 2562-2574 (2012)
2) K. Itaka, K. Kataoka, Progress and prospects of polyplex nanomicelles for plasmid DNA delivery.Curr. Gene Ther. 11 (6)
457-465 (2011))
Representative procedures to formulate for polymeric micelles using SUNBRIGHT® ME-DT and
DT series is described as follows.
SUNBRIGHT® ME-120DT70-A (Block polymer) and SUNBRIGHT® DT50-A (Homo polymer) powders were
separately dissolved in 10 mM HEPES buffer(pH 7.4) as stock solution. Mixture of stock solutions for ME-120DT70-A and DT50-A polymer at varying ME-120DT50-A / DT50-A ratios (residual molar ratio of amino groups in ME-120DT70-A and DT50-A) was added to pDNA solution for complexation at varying N/P ratios (residual molar ratio of total amino groups in ME-120DT70-A and DT50-A (N) to phosphate groups in pDNA (P)), followed by overnight incubation at 4℃. The final concentration of pDNA in all the samples was adjusted to 33.3 mg/mL.
Note that all the pre-experimental procedures involved with polymer solution or complex solution were strictly carried out at low temperature, e.g. 4℃ refrigerator or ice bath to avoid polymer degradation. Representative procedures to formulate for polymeric micelles using SUNBRIGHT® ME-DT and DT series is described as follows.
The block polymer and homo polymer belong NanoCarrier Co.,Ltd. is sold by NOF for research purpose only. In the case of use of the polymer for clinical test or commercial product, a contract is independently required.
